First AD

Second AD

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

Testing for MRD in Colorectal Cancer

Colorectal Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Advances in MRD Testing for Informed CRC Treatment

Peer Exchange

Georgetown Lombardi Comprehensive Cancer Center

Cancer Centers

Partner

Fred Hutch Cancer Center

Weill Cornell Medical College Sandra & Edward Meyer Cancer Center

Treating Colorectal Cancer: Overview of MRD Testing and ctDNA 

When is MRD Testing Performed in Colorectal Cancer Treatment?

MRD Testing Platforms in Colorectal Cancer

Colorectal Cancer: MRD Testing in the Community Setting

Practical Considerations in MRD Testing in CRC

Evolution of MRD Testing in Colorectal Cancer

Patient Profile: A 52-Year-Old Woman With Colorectal Cancer

Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan

BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer

Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD

Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

CIRCULATE-NORTH AMERICA and Barriers to Enrollment

MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

Trajectory of CRC Treatment Landscape